Dose-escalation Study to Evaluate the Safety and Tolerability of GX-I7 in Patients With Glioblastoma

NCT03619239 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

15

Enrollment

INDUSTRY

Sponsor class

Conditions

Newly Diagnosed Glioblastoma

Interventions

DRUG: GX-I7

Sponsor

Genexine, Inc.